Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

ATHA

Athira Pharma Inc

Jan 30 • 04:00PM ET

0.5340

Dollar change +0.0050
Percentage change 0.95	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB SAVA AVXL SAGE QURE PRTA INVA AUPH NBIX ANVS

| Held by: SURI VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-2.85	Insider Own	8.55%	Shs Outstand	38.67M	Perf Week	-3.77%
Market Cap	20.65M	Forward P/E	-	EPS next Y	-1.51	Insider Trans	-2.07%	Shs Float	35.36M	Perf Month	-2.89%
Income	-109.22M	PEG	-	EPS next Q	-0.41	Inst Own	47.79%	Short Float	3.87%	Perf Quarter	9.52%
Sales	0.00M	P/S	-	EPS this Y	21.60%	Inst Trans	-18.14%	Short Ratio	0.28	Perf Half Y	-83.72%
Book/sh	1.49	P/B	0.36	EPS next Y	37.67%	ROA	-80.62%	Short Interest	1.37M	Perf Year	-83.72%
Cash/sh	2.00	P/C	0.27	EPS next 5Y	-	ROE	-102.87%	52W Range	0.41 - 4.30	Perf YTD	-8.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-81.69%	ROI	-186.72%	52W High	-87.58%	Beta	2.98
Dividend TTM	-	Quick Ratio	2.95	Sales past 5Y	0.00%	Gross Margin	-	52W Low	29.77%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	2.95	EPS Y/Y TTM	10.28%	Oper. Margin	-	RSI (14)	44.54	Volatility	8.38% 7.84%
Employees	67	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	0.55
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	13.87%	Payout	-	Rel Volume	0.10	Prev Close	0.53
Sales Surprise	-	EPS Surprise	-6.88%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	4.81M	Price	0.53
SMA20	-2.98%	SMA50	-8.45%	SMA200	-66.65%	Trades		Volume	463,920	Change	0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral	$5 → $0.50
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy	$22
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30
Oct-13-20	Initiated	Goldman	Buy	$53

Show Previous Ratings

Dec-06-24 05:30PM	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-08-24 04:50AM	Athira exploring strategic alternatives after Alzheimers failure (BioPharma Dive) -12.01%
Nov-07-24 04:05PM	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire) +7.14%
Oct-22-24 07:00AM	Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting (GlobeNewswire) +15.73%
Sep-17-24 09:00AM	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
11:40AM	Loading…
Sep-04-24 11:40AM	Alzheimers Trial Failure Sends Athira Stock Down 75% (Barrons.com) -78.43%
11:33AM	Athiras stock topples after Alzheimers drug flops in Phase II/III trial (Pharmaceutical Technology)
08:48AM	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks (Benzinga)
Sep-03-24 04:01PM	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) -8.41%
Aug-23-24 09:40AM	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? (Zacks) +6.75%
Aug-07-24 09:40AM	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-01-24 04:05PM	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Jul-31-24 08:05AM	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
Jul-10-24 08:51AM	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up (Zacks)
Jul-09-24 07:00AM	Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) +29.39%
07:00AM	Loading…
Jun-12-24 07:00AM	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients (GlobeNewswire)
Jun-11-24 07:00AM	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
May-29-24 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace) +22.62%
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
04:02PM	Loading…
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33% +6.47%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +5.00%
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21% -7.26%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)
Nov-29-22 11:00AM	Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimers Disease Patients from ACT-AD Phase 2 Study at CTAD Conference (GlobeNewswire)
Nov-28-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -5.02%
Nov-21-22 07:00AM	Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Nov-16-22 07:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference (GlobeNewswire)
Nov-10-22 04:05PM	Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire) +7.97% +8.39%
Nov-09-22 07:00AM	Athira Pharma to Present at Stifel 2022 Healthcare Conference (GlobeNewswire) -7.07%
Nov-07-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference (GlobeNewswire)
Oct-30-22 08:29AM	Athira Pharma, Inc. (NASDAQ:ATHA) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Oct-17-22 07:00AM	Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients Following Independent, Unblinded Interim Analysis (GlobeNewswire) +9.03%
Sep-16-22 08:14AM	Multiple insiders bought Athira Pharma, Inc. (NASDAQ:ATHA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-06-22 03:22PM	Athira Outlines Possible Comeback For Alzheimer's Candidate (Benzinga)
07:00AM	Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients (GlobeNewswire)
Aug-20-22 08:01AM	Athira Pharma (NASDAQ:ATHA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 04:05PM	Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire)
Aug-03-22 11:28AM	Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Aug-02-22 03:30PM	Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Jul-25-22 07:00AM	Athira Pharma to Present Clinical and Preclinical Data at Alzheimers Association International Conference 2022 (GlobeNewswire)
Jul-08-22 04:19PM	Rapid Micro and Athira Pharma Stock See Action From Activist Investors (Barrons.com) -11.44%
Jun-22-22 04:49PM	Athira Pharma's stock plummets after disappointing drug trial results (American City Business Journals) -66.27%
01:29PM	Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpoint (MarketWatch)
11:31AM	Why Athira Pharma Stock Imploded Today (Motley Fool)
08:25AM	Athira says its Alzheimer's treatment did not meet endpoint in mid-stage trial; stock falls 68% (MarketWatch)

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
San Martin Javier	CHIEF MEDICAL OFFICER	Dec 31 '24	Option Exercise	0.00	46,667	0	46,667	Jan 03 05:05 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jan 02 '25	Sale	0.56	10,826	6,083	35,841	Jan 03 05:05 PM
Litton Mark James	President and CEO	Dec 31 '24	Option Exercise	0.00	108,333	0	267,698	Jan 03 05:04 PM
Litton Mark James	President and CEO	Jan 02 '25	Sale	0.56	25,107	14,108	242,591	Jan 03 05:04 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Dec 31 '24	Option Exercise	0.00	36,667	0	139,271	Jan 03 05:03 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jan 02 '25	Sale	0.56	8,510	4,782	130,761	Jan 03 05:03 PM
Renninger Robert	VP of Finance	Dec 31 '24	Option Exercise	0.00	12,359	0	92,605	Jan 03 05:01 PM
Renninger Robert	VP of Finance	Jan 02 '25	Sale	0.56	2,881	1,619	89,724	Jan 03 05:01 PM
Worthington Mark	General Counsel and CCO	Dec 31 '24	Option Exercise	0.00	36,667	0	92,245	Jan 03 05:00 PM
Worthington Mark	General Counsel and CCO	Jan 02 '25	Sale	0.56	8,510	4,782	83,735	Jan 03 05:00 PM
Javier San Martin	Officer	Jan 02 '25	Proposed Sale	0.56	10,826	6,083		Jan 02 08:06 PM
Mark James Litton	Officer	Jan 02 '25	Proposed Sale	0.56	25,107	14,108		Jan 02 08:05 PM
Mark Worthington	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:04 PM
Kevin Church	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:02 PM
Mark James Litton	Officer	Sep 05 '24	Proposed Sale	0.00	5,032	1		Sep 05 07:53 PM
Gengos Andrew	CFO and Chief Business Officer	Sep 05 '24	Sale	0.57	1,272	720	97,532	Sep 05 07:51 PM
Lenington Rachel	COO and CDO	Sep 05 '24	Sale	0.57	2,525	1,429	20,870	Sep 05 07:50 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Sep 05 '24	Sale	0.57	2,525	1,429	92,684	Sep 05 07:49 PM
Worthington Mark	GENERAL COUNSEL	Sep 05 '24	Sale	0.57	2,525	1,429	51,927	Sep 05 07:48 PM
Litton Mark James	President and CEO	Sep 05 '24	Sale	0.57	5,032	2,848	159,365	Sep 05 07:47 PM
Romano Kelly A	Director	Jun 24 '24	Buy	2.42	27,400	66,179	80,715	Jun 25 07:21 PM
Romano Kelly A	Director	Jun 21 '24	Buy	2.26	15,000	33,872	53,315	Jun 25 07:21 PM

Dollar change +0.28
Percentage change 1.40	%

ARWR Arrowhead Pharmaceuticals Inc daily Stock Chart

Peers: ALNY IONS SRPT NBIX DTIL VRTX RGNX CRSP EDIT NTLA

| Held by: IJR VTI IWM VB VXF VBK XBI SPSM IWO IJS

Index	RUT	P/E	-	EPS (ttm)	-5.00	Insider Own	6.90%	Shs Outstand	124.38M	Perf Week	-6.04%
Market Cap	2.52B	Forward P/E	-	EPS next Y	-3.36	Insider Trans	-2.18%	Shs Float	115.84M	Perf Month	6.70%
Income	-599.49M	PEG	-	EPS next Q	-0.41	Inst Own	76.25%	Short Float	8.34%	Perf Quarter	0.25%
Sales	3.55M	P/S	709.10	EPS this Y	49.91%	Inst Trans	-1.08%	Short Ratio	4.84	Perf Half Y	-29.24%
Book/sh	1.49	P/B	13.57	EPS next Y	-34.14%	ROA	-62.93%	Short Interest	9.66M	Perf Year	-41.19%
Cash/sh	5.47	P/C	3.70	EPS next 5Y	18.64%	ROE	-262.48%	52W Range	17.05 - 36.72	Perf YTD	7.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-58.15%	52W High	-44.91%	Beta	0.96
Dividend TTM	-	Quick Ratio	6.74	Sales past 5Y	-2.87%	Gross Margin	-423.66%	52W Low	18.65%	ATR (14)	1.07
Dividend Ex-Date	-	Current Ratio	6.74	EPS Y/Y TTM	-160.68%	Oper. Margin	-16927.06%	RSI (14)	51.36	Volatility	4.75% 5.37%
Employees	609	Debt/Eq	4.59	Sales Y/Y TTM	-98.52%	Profit Margin	-16882.37%	Recom	1.71	Target Price	43.42
Option/Short	Yes / Yes	LT Debt/Eq	4.56	EPS Q/Q	-34.15%	Payout	-	Rel Volume	0.73	Prev Close	19.95
Sales Surprise	-100.00%	EPS Surprise	-21.39%	Sales Q/Q	-100.00%	Earnings	Feb 10 AMC	Avg Volume	2.00M	Price	20.23
SMA20	3.12%	SMA50	-1.97%	SMA200	-10.90%	Trades		Volume	1,451,275	Change	1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60

Show Previous Ratings

Jan-22-25 05:54PM	Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 (PR Newswire) +9.23%
04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results (Business Wire)
Jan-17-25 04:30PM	Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome (Business Wire)
Dec-24-24 08:20AM	Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial (Clinical Trials Arena)
Dec-23-24 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
04:59PM	Loading…
Dec-19-24 04:59PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 07:30AM	Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases (Business Wire)
Dec-04-24 07:40AM	Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment (Clinical Trials Arena) -11.35%
Dec-03-24 07:30AM	Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
Dec-02-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences (Business Wire)
Nov-30-24 06:00AM	Arrowhead price target lowered to $24 from $27 at Bernstein (TipRanks)
Nov-29-24 01:00AM	Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance (TipRanks)
Nov-28-24 08:15AM	Sarepta price target lowered to $202 from $205 at Needham (TipRanks)
Nov-27-24 12:40PM	Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +24.23%
11:07AM	Arrowhead Stock Rockets 16% After Major Licensing Deal (GuruFocus.com)
07:21AM	Loading…
07:21AM	Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments (TipRanks)
07:20AM	Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board (TipRanks)
04:33AM	Arrowhead and Sarepta link for rare genetic disease treatments (Pharmaceutical Technology)
02:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... (GuruFocus.com)
Nov-26-24 05:18PM	Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal (Investor's Business Daily) +12.03%
04:05PM	Arrowhead Pharma, Sarepta TX ink new gene therapy deal (Yahoo Finance Video)
04:00PM	Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results (Business Wire)
09:06AM	Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta (Investor's Business Daily)
07:00AM	Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs (Business Wire)
07:00AM	Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs (Business Wire)
Nov-22-24 07:41AM	Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-19-24 03:38AM	Arrowhead Pharmaceuticals submits plozasiran NDA to treat FCS (Pharmaceutical Business Review)
Nov-18-24 07:31AM	Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome (Business Wire)
07:30AM	Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran (Business Wire)
Nov-05-24 07:30AM	Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results (Business Wire)
07:30AM	Loading…
Nov-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences (Business Wire)
Nov-01-24 07:30AM	Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, Well Get There Soon, to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome (Business Wire)
Oct-16-24 01:01PM	State Street Corp's Strategic Acquisition in Arrowhead Pharmaceuticals (GuruFocus.com) +6.14%
Oct-14-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 05:53PM	Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Sep-24-24 06:53AM	Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand (Clinical Trials Arena)
Sep-23-24 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
Sep-11-24 06:12AM	FDA grants breakthrough therapy status to Arrowheads plozasiran (Pharmaceutical Technology)
Sep-10-24 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran (Business Wire)
Sep-03-24 10:36AM	Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug (Investopedia)
06:33AM	Arrowhead to file NDA after pivotal rare disease trial meets all endpoints (Clinical Trials Arena)
Sep-02-24 06:36AM	Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire)
Aug-21-24 07:30AM	Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire) +6.95%
Aug-16-24 06:00AM	Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance (BioPharma Dive)
Aug-15-24 10:52AM	Arrowhead announces push into obesity space with two gene therapies (Pharmaceutical Technology)
Aug-14-24 01:30PM	Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies (Business Wire)
Aug-08-24 04:37PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -9.44%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results (Business Wire)
04:00PM	Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street (Business Wire)
Jul-29-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-24-24 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results (Business Wire)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-25-24 01:55PM	Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial (Business Wire)
Jun-24-24 07:30AM	Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE (Business Wire) +6.82%
Jun-03-24 03:55PM	Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? (Benzinga) +7.28%
07:30AM	Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome (Business Wire)
May-31-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences (Business Wire)
May-29-24 05:30AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-28-24 06:04AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-20-24 11:04AM	Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients (MT Newswires)
06:00AM	Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma (Business Wire)
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace)
May-10-24 01:03PM	Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations (GuruFocus.com) -10.68%
12:26PM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript (Insider Monkey)
11:32AM	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating (MT Newswires)
May-09-24 11:54PM	ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 (InvestorPlace)
04:34PM	Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 (MT Newswires)
04:14PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results (Business Wire)
May-03-24 07:26AM	Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug (MT Newswires)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
Apr-29-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences (Business Wire)
Apr-26-24 07:30AM	Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars (Business Wire)
Apr-24-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results (Business Wire) -6.10%
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease (Business Wire)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-07-24 09:00AM	Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo (Business Wire)
Apr-04-24 01:27AM	Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ... (GuruFocus.com)
Apr-01-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -7.26%
Mar-25-24 08:00AM	Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data (Business Wire)
Mar-11-24 06:53PM	The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 (InvestorPlace) -12.11%
Mar-08-24 11:29PM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares (GuruFocus.com)
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy (Business Wire)
Mar-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences (Business Wire)
Feb-07-24 10:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:02AM	Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-24 04:32PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:32PM	Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ... (GuruFocus.com)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results (Business Wire)
Jan-22-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results (Business Wire)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-09-24 03:02AM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares (GuruFocus.com)
Jan-06-24 01:01PM	Arrowhead Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-05-24 05:00PM	Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million (Business Wire) +10.90%
11:02AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 9,952 Shares (GuruFocus.com)
Jan-03-24 07:00AM	Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock (Business Wire)
Dec-29-23 04:01PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-24-23 09:01AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares (GuruFocus.com)
Dec-21-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease (Business Wire)
Dec-20-23 07:30AM	Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.23%

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OLUKOTUN ADEOYE Y	Director	Jan 23 '25	Sale	21.00	959	20,139	35,781	Jan 27 07:22 PM
OLUKOTUN ADEOYE Y	Director	Jan 23 '25	Proposed Sale	20.97	959	20,108		Jan 23 04:43 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 06 '25	Sale	19.82	32,729	648,824	272,122	Jan 07 09:28 PM
O'Brien Patrick	COO and General Counsel	Jan 06 '25	Sale	19.82	29,184	578,539	535,201	Jan 07 09:28 PM
O'Brien Patrick	COO and General Counsel	Jan 07 '25	Sale	19.69	8,000	157,520	527,201	Jan 07 09:28 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 06 '25	Sale	19.83	27,167	538,595	473,433	Jan 07 09:27 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 07 '25	Sale	19.69	18,000	354,500	455,433	Jan 07 09:27 PM
Myszkowski Kenneth Allen	Officer	Jan 07 '25	Proposed Sale	19.69	10,000	196,877		Jan 07 05:01 PM
Myszkowski Kenneth Allen	Officer	Jan 07 '25	Proposed Sale	19.69	8,000	157,529		Jan 07 04:49 PM
O'Brien Patrick	Officer	Jan 07 '25	Proposed Sale	19.69	8,000	157,507		Jan 07 04:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '25	Sale	19.05	11,520	219,456	3,764,252	Jan 06 06:07 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	5,817	115,318		Jan 06 05:48 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	9,255	183,476		Jan 06 05:40 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.80	6,287	124,452		Jan 06 05:33 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	5,817	115,320		Jan 06 05:26 PM
Hamilton James C	Officer	Jan 06 '25	Proposed Sale	19.82	32,729	648,743		Jan 06 05:19 PM
O'Brien Patrick	Officer	Jan 06 '25	Proposed Sale	19.82	29,184	578,456		Jan 06 05:05 PM
Anzalone Christopher Richard	Officer	Jan 02 '25	Proposed Sale	19.04	11,520	219,392		Jan 02 04:16 PM
OLUKOTUN ADEOYE Y	Director	Dec 27 '24	Sale	20.00	2,850	57,000	36,740	Dec 30 05:12 PM
OLUKOTUN ADEOYE Y	Director	Dec 27 '24	Proposed Sale	19.99	2,850	56,968		Dec 27 04:23 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 23 '24	Sale	19.59	12,563	246,109	3,775,772	Dec 23 04:39 PM
Anzalone Christopher Richard	Officer	Dec 23 '24	Proposed Sale	19.59	12,563	246,085		Dec 23 04:16 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 18 '24	Sale	21.24	26,712	567,486	3,688,335	Dec 20 06:04 PM
Waddill William D.	Director	Dec 17 '24	Sale	22.04	3,747	82,584	40,378	Dec 18 06:19 PM
Waddill William D.	Director	Dec 16 '24	Sale	21.90	3,748	82,081	44,125	Dec 18 06:19 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Sale	21.90	5,000	109,500	124,714	Dec 18 06:18 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Sale	22.04	547	12,056	124,167	Dec 18 06:18 PM
Vakiener Victoria	Director	Dec 16 '24	Sale	21.91	8,994	197,059	21,211	Dec 18 06:15 PM
Anzalone Christopher Richard	Officer	Dec 18 '24	Proposed Sale	21.24	26,712	567,415		Dec 18 04:41 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Proposed Sale	21.98	547	12,026		Dec 17 05:06 PM
Waddill William D.	Director	Dec 17 '24	Proposed Sale	22.03	3,747	82,552		Dec 17 04:53 PM
Waddill William D.	Director	Dec 16 '24	Proposed Sale	21.89	3,748	82,056		Dec 16 04:44 PM
Vakiener Victoria	Director	Dec 16 '24	Proposed Sale	21.91	8,994	197,066		Dec 16 04:30 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Proposed Sale	21.89	5,000	109,470		Dec 16 04:15 PM
Oliver Tracie	Chief Commercial Officer	Jul 02 '24	Sale	25.28	9,394	237,480	127,107	Jul 03 05:27 PM
Vakiener Victoria	Director	May 02 '24	Sale	23.31	1,799	41,935	30,205	May 06 06:04 PM
Hamilton James C	Chief Discovery/Trans Medicine	Apr 01 '24	Sale	28.03	6,000	168,180	204,851	Apr 03 06:05 PM
Lu Hongbo	Director	Mar 19 '24	Buy	28.00	1,000	28,000	32,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 20 '24	Buy	27.50	1,000	27,500	33,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 18 '24	Buy	27.49	1,000	27,490	31,680	Mar 20 07:06 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Mar 06 '24	Sale	35.19	40,000	1,407,600	400,600	Mar 08 05:54 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Option Exercise	14.54	57,499	836,035	3,772,547	Feb 02 05:25 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Sale	32.35	57,499	1,860,019	3,715,048	Feb 02 05:25 PM

ATHA

Athira Pharma Inc

ARWR

Arrowhead Pharmaceuticals Inc

Upgrade your FINVIZ experience